This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Protagonist (PTGX) Begins Dosing in Phase I Study With PN-235
by Zacks Equity Research
Protagonist Therapeutics (PTGX) doses the first patient in a phase I study on its oral IL-23 receptor antagonist, PN-235, being developed in collaboration with Janssen Biotech. Shares rise.
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 65.57% and 245.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics (PTGX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.51% and 63.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protagonist Therapeutics' PTG-300 Gets FDA's Orphan Drug Tag
by Zacks Equity Research
The FDA bestows an orphan drug status on Protagonist Therapeutics' (PTGX) PTG-300 injection for treating patients with polycythemia vera. It is also being developed for hereditary hemochromatosis.
Company News for May 11, 2020
by Zacks Equity Research
Companies In The News Are: FTEK, PTGX, SXC, ZG
Why Did Protagonist Therapeutics (PTGX) Soar 83.7% Today?
by Madeleine Johnson
Shares of micro-cap biopharmaceutical company Protagonist Therapeutics (PTGX) soared on Friday, and were up over 90% at one point in afternoon trading.
Protagonist Therapeutics (PTGX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 1.56% and -48.21%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Protagonist Therapeutics (PTGX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protagonist (PTGX) Starts Study on PTG-300 for Blood Disorder
by Zacks Equity Research
Protagonist's (PTGX) phase II study on PTG-300 will evaluate it as a potential treatment for hereditary hemochromatosis, a rare blood disorder, caused due to accumulation of iron.
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 18.67% and -27.98%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Protagonist Therapeutics (PTGX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -337.04% and -176.06%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 10.77% and -37.60%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Protagonist Therapeutics (PTGX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 5.00% and -3.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics (PTGX) Q3 Earnings Preview: What to Know Ahead of the Release
by Zacks Equity Research
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -36.67% and 36.54%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotech (PBYI) Q1 Loss Narrows, Sales Miss, Stock Down
by Zacks Equity Research
Puma Biotechnology (PBYI) Q1 loss per share is narrower than the Zacks Consensus Estimate while sales misses the same.
Infinity (INFI) Incurs In-Line Loss in Q1, Maintains View
by Zacks Equity Research
Infinity (INFI) reports in-line loss in Q1 and maintains its 2018 guidance.
Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Epizyme (EPZM) betters loss estimates in Q1 and expects to file a new drug application to the FDA for its lead pipeline candidate tazemetostat in fourth-quarter 2018.
Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Merrimack (MACK) reports wider-than-expected loss in the first quarter.
Arena Pharmaceuticals (ARNA) Q1 Loss Wider Than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reports wider-than-expected Q1 loss. Its three key pipeline candidates - ralinepag, etrasimod and Olorinab/APD371 - remain in focus.